[1] Zhang Z, Zhang L L, Feng Y G, et al.Research on the optimization of pharmacovigilance laws and regulations in China[J]. Asian Journal of Social Pharmacy, 2025, 20(2): 116-125. [2] Mireault M, Rose C F, Karvellas C J, et al.Perturbations in human bile acid profiles following drug-induced liver injury investigated using semitargeted high-resolution mass spectrometry[J]. Rapid Commun Mass Spectrom, 2024, 38(9): e9731. [3] Mireault M, Prinville V, Ohlund L, et al.Semi-targeted profiling of bile acids by high-resolution mass spectrometry in a rat model of drug-induced liver injury[J]. Int J Mol Sci, 2023, 24(3): 2489. [4] Liu Z, You C.The bile acid profile[J]. Clin Chim Acta, 2025, 565: 120004. [5] Zhao X, Liu Z, Sun F, et al.Bile acid detection techniques and bile acid-related diseases[J]. Front Physiol, 2022, 13: 826740. [6] Beaudoin J J, Yang K, Adiwidjaja J, et al.Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition[J]. Front Pharmacol, 2022, 13: 1085621. [7] Cortese M, Gigliobianco M R, Magnoni F, et al.Compensate for or minimize matrix effects? strategies for overcoming matrix effects in liquid chromatography-mass spectrometry technique: a tutorial review[J]. Molecules, 2020, 25(13): 3047. [8] Roumain M, Muccioli G G.Development and application of an LC-MS/MS method for the combined quantification of oxysterols and bile acids[J]. J Lipid Res, 2025, 66(1): 100697. [9] Zhang X, Li K, Xian R, et al.Quantification of glucose in the plasma of healthy Chinese volunteers and a bioequivalence study using a surrogate matrix approach combined with UHPLC-MS/MS[J]. Anal Methods, 2025, 17(13): 2708-2717. [10] Isokääntä H, Strang E, Bucci V, et al.Comparative metabolomics and microbiome analysis of human fecal samples preserved with ethanol[J]. Anal Chem, 2024, 96(23): 9335-9344. [11] Chen W, Xie Y, Li Q, et al.Update of safety profile of bile acid sequestrants: a real-world pharmacovigilance study of the FDA adverse event reporting system[J]. PLoS One, 2025, 20(7): e0328371. [12] Asano T, Taki K, Kitamori K, et al.One-pot extraction and quantification method for bile acids in the rat liver by capillary liquid chromatography tandem mass spectrometry[J]. ACS Omega, 2021, 6(12): 8588-8597. [13] Zhang X, Liu X, Yang J, et al.Quantitative profiling of bile acids in feces of humans and rodents by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry[J]. Metabolites, 2022, 12(7): 633. [14] Hu X, Liu C, Zhou J, et al.Advances in the recognition strategies and analytical techniques of bile acids[J]. TrAC Trends Anal Chem, 2024, 180: 117984. [15] Zheng D, Ge K, Qu C, et al.Comparative profiling of serum, urine, and feces bile acids in humans, rats, and mice[J]. Commun Biol, 2024, 7(1): 641. [16] Yang J, Lin J, Wang A, et al.Study on the effect of calibration standards prepared with different matrix on the accuracy of bile acid quantification using LC-MS/MS[J]. J Pharm Biomed Anal, 2024, 237: 115785. [17] Ma Y, Cao Y, Song X, et al.BAFinder: a software for unknown bile acid identification using accurate mass LC-MS/MS in positive and negative modes[J]. Anal Chem, 2022, 94(16): 6242-6250. [18] Lányi K, Kiss D S, Süth M, et al.A novel approach to quantitative profiling of bile acids in dog blood serum by means triple quadruple LC-MS/MS: a step-by-step method optimization[J]. Microchem J, 2025, 208: 112495. [19] Wang X, Wang Y, Zhang X, et al.Historical process, status and future development of pharmacovigilance systems in Chinese medicine[J]. Pharmacy, 2025, 13(4): 90. |